ArticleAntimicrobial agents and chemotherapy2010
Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- Management of COVID-19-associated multisystem inflammatory syndrome in children: A comprehensive literature review.Progress in pediatric cardiology · 2021Review
- A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy.Journal of cardiovascular translational research · 2021Review
- Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations.bioRxiv : the preprint server for biology · 2020Article
- Review
- Hormesis and Defense of Infectious Disease.International journal of molecular sciences · 2017Review
- Interference of the T Cell and Antigen-Presenting Cell Costimulatory Pathway Using CTLA4-Ig (Abatacept) Prevents Staphylococcal Enterotoxin B Pathology.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.The Journal of clinical investigation · 2017Article
- FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights.ImmunoTargets and therapy · 2017Review
- Staphylococcal Superantigens Spark Host-Mediated Danger Signals.Frontiers in immunology · 2016Review
- Δ(9) Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells.British journal of pharmacology · 2015Article
- Neutralization of staphylococcal enterotoxin B by an aptamer antagonist.Antimicrobial agents and chemotherapy · 2015Article
- Drug repurposing for the treatment of staphylococcal infections.Current pharmaceutical design · 2015Review
- Defective autophagy impairs ATF3 activity and worsens lung injury during endotoxemia.Journal of molecular medicine (Berlin, Germany) · 2014Article
- Mesenchymal stromal (stem) cells suppress pro-inflammatory cytokine production but fail to improve survival in experimental staphylococcal toxic shock syndrome.BMC immunology · 2014Article
- Late multiple organ surge in interferon-regulated target genes characterizes staphylococcal enterotoxin B lethality.PloS one · 2014Article
- Bacterial Toxins-Staphylococcal Enterotoxin B.Microbiology spectrum · 2013Article
- The staphylococcal enterotoxin (SE) family: SEB and siblings.Virulence · 2013Review
- Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions.Toxins · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcal enterotoxins are potent activators for human T cells and cause lethal toxic shock. Rapamycin, an immunosuppressant, was tested for its ability to inhibit staphylococcal enterotoxin B (SEB)-induced activation of human peripheral blood mononuclear cells (PBMC) in vitro and toxin-mediated shock in mice. Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation. In vivo, rapamycin protected 100% of mice from lethal shock, even when administered 24 h after intranasal SEB challenge. The serum levels of MCP-1 and IL-6, after intranasal exposure to SEB, were significantly reduced in mice given rapamycin versus controls. Additionally, rapamycin diminished the weight loss and temperature fluctuations elicited by SEB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.